Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 6Terminated 2Completed 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 8Recurrence 2Leukemia, Myelomonocytic, Chronic 2Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Melanoma 1Medulloblastoma 1Lymphoma 1Leukemia 1Graft vs Host Disease 1Ependymoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

siremadlin 1selinexor 1posaconazole 1midostaurin 1fludarabine 1durvalumab 1blinatumomab 1avelumab 1Radiosurgery 1Midazolam 1Lenalidomide 1Idarubicin 1Dexamethasone 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Calcium Dobesilate 1Azacitidine 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm, Residual × Azacitidine × Clear all
NCT03699384 2019-02-20

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡